| 產品名稱 |
NCI-H727 [H727] |
| 商品貨號 |
B165363 |
| Organism |
Homo sapiens, human |
| Tissue |
lung, bronchus |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
carcinoid |
| Age |
65 years |
| Gender |
female |
| Ethnicity |
Caucasian |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from tissue taken prior to therapy. |
| Clinical Data |
65 years
Caucasian
female
This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from tissue taken prior to therapy. |
| Receptor Expression |
epidermal growth factor (EGF) |
| Genes Expressed |
neuromedin B (NMB) |
| Cellular Products |
neuromedin B (NMB) |
| Comments |
This is the best differentiated of the available bronchial carcinoid lines.
The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.
The cells are able to synthesize the peptide NMB (at 0.1 pmol/mg protein), but not the gastrin releasing peptide (GRP).
The cell line secretes a parathyroid hormone-like protein which is calcium stimulated through a protein kinase C pathway.
Growth of NCI-H727 cells is inhibited by epidermal growth factor (EGF) receptor monoclonal antibodies. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
div>Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 11,13 D5S818: 11,12 D7S820: 8,10 THO1: 8 TPOX: 8 vWA: 14,15 |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| References |
Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
Brandt DW, et al. Calcium-stimulated parathyroid hormone-like protein secretion: potentiation through a protein kinase-C pathway. Endocrinology 128: 2999-3004, 1991. PubMed: 2036974
Giaccone G, et al. Neuromedin B is present in lung cancer cell lines. Cancer Res. 52: 2732s-2736s, 1992. PubMed: 1563005
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
Natl. Cancer Inst. Monogr. 13: 117-123, 1992.
|
